Antibiotic pharmacodynamics and bacterial resistance: Usefulness of in vitro models Stephen H. ZinnerAlexander Firsov Invited Commentary 27 April 2007 Pages: 175 - 177
Web alert Carlene A. Muto MD, MS Division of Infectious Diseases, University of Pittsburgh Medical Center, 1215 Kaufmann Building, 3471 Fifth Avenue, Pittsburgh, PA 15213, USA. E-mail: mutoca@upmc.edu EditorialNotes 27 April 2007 Pages: 178 - 179
Bacterial biofilm in upper respiratory tract infections David P. Morris OriginalPaper 27 April 2007 Pages: 186 - 192
Anti-inflammatory treatment of chronic rhinosinusitis: A shifting paradigm Umur HatipoğluIsrael Rubinstein OriginalPaper 27 April 2007 Pages: 193 - 200
Nasal colonization with methicillin-resistant Staphylococcus aureus: Clinical implications and treatment David FriedelMichael Climo OriginalPaper 27 April 2007 Pages: 201 - 207
The role of anaerobic bacteria in upper respiratory tract and other head and neck infections Itzhak Brook OriginalPaper 27 April 2007 Pages: 208 - 217
Do all patients with community-acquired pneumonia need antibiotics within 4 hours of presentation? Janet R. Maurer Clinical Trials Report 27 April 2007 Pages: 221 - 222
Methicillin-resistant Staphylococcus aureus as a cause of community-acquired pneumonia Curt StankovicPrashant V. MahajanBasim I. Asmar OriginalPaper 27 April 2007 Pages: 223 - 227
Pulmonary infections in the HIV-infected patient in the era of highly active antiretroviral therapy: An update Deepa G. LazarousAnne E. O’Donnell OriginalPaper 27 April 2007 Pages: 228 - 232
Procalcitonin and pneumonia: Is it a useful marker? Mirjam Christ-CrainBeat Müller OriginalPaper 27 April 2007 Pages: 233 - 240
Tuberculosis, drug resistance, and HIV/AIDS: A triple threat Gerald Friedland OriginalPaper 27 April 2007 Pages: 252 - 261
